

NEW!

Refresh® FUSION Preservative-Free



Two lubricants. One drop.

An exclusive combination of CMC and HA for rapid and lasting relief of dry eye disease.*^{1,2}

Refresh FUSION is indicated for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to environmental conditions. Refresh FUSION is also indicated for post-surgical use (LASIK). Refresh FUSION helps to protect against further irritation.

CMC=carboxymethyl cellulose; HA=hyaluronic acid.

* The CMC + HA combination is exclusive to the FUSION family of products. In addition to CMC and HA, Refresh FUSION contains the lubricant glycerin.



**Refresh®
FUSION**

Rapid and lasting relief of DED symptoms

Refresh FUSION combines CMC and HA, for effective moisturization and long-lasting ocular surface hydration.^{1,2}

In a 3-month study of patients with dry eye, Refresh FUSION[†] demonstrated:^{1‡}

Significant changes vs. baseline in OSDI scores.[§]

Refresh FUSION demonstrated significant improvements in OSDI scores from baseline from day 7 through day 90 ($p \leq 0.001$). Refresh FUSION was noninferior to Refresh TEARS in change in OSDI score from baseline at day 90 (Refresh Fusion -14.7 ± 16.3 [$n=101$]; Refresh TEARS -14.5 ± 16.4 , [$n=104$]) (primary endpoint, ITT population; treatment difference -0.22 [95% CI: -4.85 to 4.41]; non-inferiority margin of 7.3).

Significant improvements in dry eye symptoms of burning/stinging, grittiness, dryness, and pain vs. baseline.

($p \leq 0.002$ vs. baseline for each symptom at day 90.[¶] [within-group comparison, other endpoint, ITT population])

Significant improvements in tear film break-up time (TBUT) vs. baseline.

(Mean change from baseline in TBUT at day 90 was 1.65 ± 4.26 s [baseline TBUT 5.24 ± 2.01 s; $p < 0.001$]. [within-group comparison, secondary endpoint, ITT population])



CMC and HA work together to relieve the symptoms of DED.^{1,2}

DED=dry eye disease; CMC=carboxymethyl cellulose; HA=hyaluronic acid; OSDI=Ocular Surface Disease Index; ITT=intent-to-treat; CI=confidence interval.

[†] The studied agent was OPTIVE FUSION, which differs from Refresh FUSION only in that it is preserved with PURITE (stabilized oxychloro complex). OPTIVE FUSION (preserved multi-dose formulation) and Refresh FUSION (unpreserved multi-dose formulation) are clinically equivalent.


[‡] 3-month, multicentre, randomized, double-masked, parallel-group clinical comparison study evaluating OPTIVE FUSION ($n=101$) compared with Refresh TEARS ($n=104$) in subjects with dry eye. Participants were adults with mild-to-severe symptoms and mild-to-moderate signs of dry eye, an OSDI score of 18–65, tear breakup time (TBUT) less than 10 seconds, and currently used artificial tears. Follow-up study visits were scheduled at days 7, 30, 60, and 90.

[§] The OSDI score is based on a scale of 0–100, where 100 corresponds to complete disability (a response of “all of the time” to all questions answered). A negative change from baseline indicates improvement. OSDI baseline score in the Refresh FUSION group was 36.8 ± 13.4 and 38.9 ± 11.9 for Refresh TEARS.

Protection against further DED irritation

Refresh FUSION[†] reduced the signs of ocular surface disease as demonstrated by improvements in corneal staining scores.^{1,†¶}

Change in corneal staining over 90 days^{1,3,† ††} (secondary endpoint, ITT population)



Adapted from Simmons, et al, 2015. Additional data is on file.



Refresh FUSION contains osmoprotectants that can protect the ocular surface against hyperosmolarity and further cell damage.⁴

¶ Mean symptom score for Refresh FUSION at day 90: Burning/stinging 27.0 (baseline score 40), Grittiness 28.0 (baseline score 44.5), Dryness 37.0 (baseline score 61.1), Pain 20.5 (baseline score 32.1); $p < 0.001$ vs. baseline for all symptoms.

†† Corneal staining was evaluated using a slit lamp at 16 \times magnification and a yellow filter to enhance contrast and rated based on the modified National Eye Institute (NEI) grid, which assesses five areas of the cornea on a scale of 0–5.

Refresh[®]
FUSION

NEW!

Refresh® FUSION Preservative-Free

A new option for patients with aqueous-deficient DED...

- ✓ An exclusive combination of CMC, HA and osmoprotectants*^{1,2}
- ✓ Provides rapid relief and lasting lubrication⁷
- ✓ Helps protect against further irritation⁷
- ✓ Indicated for post-surgery use and compatible with contact lenses⁵⁻⁷

See warnings, cautions and directions of use at refreshbrand.ca for information to assist in benefit-risk assessment. Always direct the patient to read the label. The Terms of Market Authorization is also available by calling 1-888-704-8271.

DED=dry eye disease; CMC=carboxymethyl cellulose; HA=hyaluronic acid.

* The CMC + HA combination is exclusive to the FUSION family of products.

References: 1. Simmons P, Liu H, Carlisle-Wilcox C, *et al.* Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial. *Clin Ophthalmol.* 2015;9:665–75. 2. Simmons P and Vehige JG. Investigating the potential benefits of a new artificial tear formulation combining two polymers. *Clin Ophthalmol.* 2017;11:1637. 3. Allergan Ltd. Data on file. CSR 10078X-001. 2013. 4. Baudouin C, Aragona P, Messmer EM, *et al.* Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. *Ocul Surf.* 2013;11:246–58. 5. Nichols JJ, Lievens CW, Bloomenstein MR, *et al.* Dual-polymer drops, contact lens comfort, and lid wiper epitheliopathy. *Optom Vis Sci.* 2016;93(8):979–86. 6. Wallerstein A, Jackson WB, Chambers J, *et al.* Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose. *Clin Ophthalmol.* 2018;12:839–48. 7. Refresh® FUSION Labelling, 2024.

abbvie

Refresh Fusion and its design are trademarks of AbbVie Corporation.
© 2024 AbbVie. All rights reserved.

CA-RFS-230061A / MA24



Refresh®
FUSION